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Introduction: Break-apart fluorescence in situ hybridization 
(FISH) is the FDA-approved assay for detecting anaplastic lym-
phoma kinase (ALK) rearrangements in non–small-cell lung can-
cer (NSCLC), identifying patients who can gain dramatic beneﬁt 
from ALK kinase inhibitors. Assay interpretation can be techni-
cally challenging, and either splitting of the 5′ and 3′ probes or 
loss of the 5′ probe constitute rearrangement. We hypothesized 
that there may be clinical differences depending on rearrangement 
pattern on FISH.
Methods: An IRB-approved database of NSCLC patients at 
Dana-Farber Cancer Institute was queried for ALK rearrangement. 
Clinical characteristics and response to crizotinib were reviewed. 
Immunohistochemistry (IHC) and targeted next-generation sequenc-
ing (NGS) were obtained when available.
Results: Of 1614 NSCLC patients with ALK testing, 82 patients 
(5.1%) had ALK rearrangement by FISH: 30 patients with split sig-
nals, 25 patients with 5′ deletion, and 27 patients with details unavail-
able. Patients with 5′ deletion were older (p = 0.01) and tended to 
have more extensive smoking histories (p = 0.08). IHC was positive 
for ALK rearrangement in all 27 patients with FISH split signals, 
whereas three of 21 patients with FISH 5′ deletion had negative IHC 
(p = 0.05). Targeted NGS on two of three cases with discordant FISH 
and IHC results did not identify ALK rearrangement, instead ﬁnd-
ing driver mutations in EGFR and KRAS. Patients with 5′ deletion 
treated with crizotinib had a smaller magnitude of tumor response 
(p = 0.03).
Conclusions: Patients with 5′ deletion on ALK FISH harbor features 
less typical of ALK-rearranged tumors, potentially indicating that 
some cases with this variant are false positives. Corroborative testing 
with IHC or NGS may be beneﬁcial.
Key Words: Anaplastic lymphoma kinase rearrangement, 
Crizotinib, Non–small-cell lung cancer, Fluorescence in situ 
hybridization.
(J Thorac Oncol. 2015;10: 1648–1652)
Rearrangement of the anaplastic lymphoma kinase (ALK) gene results in expression of a potent oncogenic driver in 
3% to 5% of non–small-cell lung cancer (NSCLC).1,2 Patients 
with ALK rearrangement tend to be younger in age and have 
less extensive smoking histories.3 Identiﬁcation of lung can-
cers harboring ALK rearrangements is important clinically as 
these cancers have a 50% to 60% response rate to crizotinib, 
with improved progression-free survival compared with con-
ventional chemotherapy.4,5
Crizotinib approval by the FDA was accompanied by a 
commercially available diagnostic assay for ALK rearrange-
ment—the Vysis ALK Break Apart fluorescence in situ hybrid-
ization (FISH) Probe Kit. The assay utilizes DNA probes that 
hybridize to the 3′ and 5′ regions of the common fusion break-
point in ALK; rearrangement is identiﬁed by either splitting of 
the 3′ and 5′ signals or loss of the 5′ signal in greater than or 
equal to 12% of nuclei (Fig. 1). Interpretation of ALK break-
apart FISH can be technically challenging due to subtlety 
of signals that fade over time and interobserver variability. 
Furthermore, a proportion of cells in ALK-positive tumors 
may have no detectable rearrangement by FISH, whereas a 
small number of cells in normal tissue may yield patterns con-
sistent with rearrangement.6
Here, we study the clinical and pathologic charac-
teristics of patients with split signals versus 5′ deletion on 
ALK FISH. We hypothesized that there may be differences 
between these two populations that might indicate an unap-
preciated risk of false-positive results using ALK break-
apart FISH.
MATERIALS AND METHODS
An institutional database of NSCLC patients was que-
ried for those identiﬁed to harbor ALK rearrangement on 
FISH between 2009 and 2014. In general, the predominant 
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ALK FISH pattern was used to characterize the sample as 
either split signal or 5′ deletion. Patients with insufﬁcient 
information regarding the speciﬁc type of ALK FISH abnor-
mality were excluded from analysis. ALK immunohistochem-
istry (IHC) was performed using the monoclonal antibody 
5A4 (Novocastra, Newcastle, UK), and any tumor with at 
least multifocal low to moderate cytoplasmic expression was 
considered positive.7 Next-generation sequencing (NGS) 
was performed by means of a targeted hybrid capture panel 
that detects mutations, insertions, deletions, copy number 
changes, and rearrangements within exons and key introns of 
645 cancer-associated genes, including ALK. Objective tumor 
response was determined by Response Evaluation Criteria 
in Solid Tumors version 1.1, and best overall response dur-
ing therapy was obtained for each patient.8 Maximal tumor 
shrinkage was calculated using the smallest sum of target 
lesions after baseline, in reference to baseline measurements. 
A one-sided Wilcoxon Mann–Whitney test was used to test 
the hypothesis that 5′ deletion tumors are less responsive to 
crizotinib. Statistical analyses were performed using SAS ver-
sion 9.1 (SAS Institute Inc., Cary, NC).
RESULTS
Patient Characteristics
Of 1614 NSCLC patients who underwent ALK test-
ing, 82 patients (5.1%) had ALK rearrangement identiﬁed 
by means of FISH. Of those, 30 patients (37%) showed 
split signals and 25 patients (30%) showed 5′ deletion. The 
remaining 27 patients (33%) had insufﬁcient details regard-
ing the speciﬁc pattern identiﬁed on FISH, with many tested 
using an alternative FISH assay during the early days of 
ALK genotyping, predating the current break-apart FISH. 
The median number of FISH-positive nuclei in cases with 
split signals was 62%, compared with 81% in cases with 5′ 
deletion. Relative to patients with split signals, those with 5′ 
deletion were older (median age: 58 versus 50; p = 0.01) and 
tended to have more extensive smoking histories (p = 0.08; 
Table 1). There were no signiﬁcant differences between the 
two groups with regard to gender, race, and tumor histology 
(all adenocarcinoma).
Immunohistochemistry and Targeted 
Next-Generation Sequencing
Tissue was available to perform ALK IHC in 27 of 30 
samples demonstrating split signals on FISH and 21 of 25 
samples demonstrating 5′ deletion (Table 1). All 27 samples 
with split signals were also positive for ALK rearrangement 
by IHC, whereas three of 21 samples with 5′ deletion were 
negative for ALK rearrangement by IHC. The three cases with 
positive FISH and negative IHC results had between 38% and 
48% nuclei positive for 5′ deletion by FISH.
Targeted NGS was performed on a total of 13 available 
samples, including two of the three cases with discordant 
ALK FISH and IHC results. Neither of the two specimens 
with discordant FISH and IHC results was found to harbor 
ALK rearrangement by NGS. Instead, NGS identiﬁed alter-
nate driver mutations in both cases, one in EGFR (L858R) 
and the other in KRAS (Q61L). An additional eight cases 
FIGURE 1. ALK break-apart FISH utilizes DNA 
probes that hybridize to the 3′ (red signal) and 
5′ (green signal) regions of the common fusion 
breakpoint in ALK. Rearrangement may be identified 
by two variant FISH patterns—splitting of signals 
and 5′ deletion. A, ALK rearrangement is identified 
by splitting of the red and green signals in both 
nuclei in this field. B, Rearrangement is identified 
by a single red signal (red arrow) with loss of the 5′ 
green signal in one of the four nuclei observed. An 
additional three nuclei demonstrate overlapping of 
the 3′ and 5′ probes, reflecting wild-type ALK. ALK, 
anaplastic lymphoma kinase; FISH, fluorescence in 
situ hybridization.
TABLE 1.  Patient Characteristics of FISH Split Signals vs.  
5′ Deletion
Split Signals (n = 30) 5′ Deletion (n = 25) p
Age at diagnosis (years)
  Median 50 58 0.01
  Range 22–82 28–76
Sex
  Women 18 (60%) 17 (68%) 0.55
  Men 12 (40%) 8 (32%)
Race
  Caucasian 24 (80%) 22 (88%) 0.83
  Asian 2 (7%) 2 (8%)
  Others 4 (13%) 1 (4%)
Smoking history
  Never smoker 19 (63%) 11 (44%) 0.08
  0–5 pack-years 6 (20%) 1 (4%)
  5–15 pack-years 1 (3%) 8 (32%)
  ≥15 pack-years 4 (13%) 5 (20%)
Split Signals (n = 27) 5′ Deletion (n = 21) p
Immunohistochemistry
  Positive 27 (100%) 18 (86%) 0.05
  Negative 0 (0%) 3 (16%)
FISH, fluorescence in situ hybridization.
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with FISH 5′ deletion and three cases with split signals 
demonstrated ALK rearrangement by NGS, and all were 
IHC positive. Ten of the 11 cases with ALK rearrangement 
detected by NGS showed sequencing evidence of an EML4-
ALK rearrangement. A single case contained a DCTN1-ALK 
rearrangement, a rarely reported fusion that has been associ-
ated with response to crizotinib therapy in ALK-rearranged 
inflammatory myoﬁbroblastic tumor.9 No other driver alter-
ations were seen in cases with ALK rearrangement detected 
by NGS.
Response to Crizotinib
Twenty-six patients who received crizotinib had req-
uisite radiologic follow-up for analysis of response. Of 11 
patients with split signals, eight patients had partial response 
(73%), three patients had stable disease, and none had disease 
progression as the overall response (Fig. 2). Of 15 patients 
with 5′ deletion, nine patients had partial response (60%), 
four patients had stable disease, and two patients had disease 
progression, including one case with new liver metastases. 
Patients with split signals on ALK FISH had greater median 
decrease in tumor diameter (48%) than patients with 5′ dele-
tion (38%; p = 0.03).
All three patients with discordant ALK FISH and IHC 
results were treated with crizotinib, with two out of the three 
showing disease progression. The patient with KRAS Q61L 
mutation showed a 30% increase in tumor size (Fig. 3), 
whereas the patient with EGFR L858R mutation showed a 
12% decrease in tumor size, but presence of new liver metas-
tases. The ﬁnal case with conflicting FISH and IHC results, 
FIGURE 2. Patients with split signals on ALK FISH 
had a median decrease in tumor diameter of 48% 
compared with patients with 5′ deletion on ALK 
FISH (38%; p = 0.03). Of 11 patients with split 
signals, eight patients had partial response, three 
patients had stable disease, and none had disease 
progression. Of 15 patients with 5′ deletion, nine 
patients had partial response, four patients had 
stable disease, and two patients had disease pro-
gression, including one case with new liver metas-
tases. Two of the three cases with discordant FISH 
and IHC results showed disease progression—both 
cases were negative for ALK rearrangement by NGS. 
ALK, anaplastic lymphoma kinase; FISH, fluorescence 
in situ hybridization; IHC, immunohistochemistry; 
NGS, next-generation sequencing.
FIGURE 3. Progression of disease through crizo-
tinib in a 71-year-old patient with a heavy smoking 
history who was positive for ALK rearrangement 
by FISH 5′ deletion, but negative by IHC and NGS. 
NGS found the tumor to be wild type for ALK and 
instead identified a Q61L KRAS mutation. Treatment 
with crizotinib over 8 weeks yielded no radiologic 
response, with an increase in the tumor size by 30%. 
ALK, anaplastic lymphoma kinase; FISH, fluorescence 
in situ hybridization; IHC, immunohistochemistry; 
NGS, next-generation sequencing.
1651Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ® • Volume 10, Number 11, November 2015 Variant ALK FISH Rearrangement Patterns
which had insufﬁcient tissue for NGS, showed partial response 
to crizotinib, with a 34% maximal decrease in tumor size.
DISCUSSION
ALK break-apart FISH has been the diagnostic assay 
used for patient selection in major trials involving ALK-
targeted TKIs4,5 and remains the only FDA-approved test 
for ALK rearrangement. While the incidence of various ALK 
FISH patterns has been previously reported,10 ours is the ﬁrst 
study examining the clinical and pathologic characteristics 
of the two FISH patterns that constitute ALK rearrangement. 
Compared with patients with FISH split signals, those with 
5′ deletion in our analysis were more likely to harbor char-
acteristics less typical of ALK-rearranged patients, including 
older age and more extensive smoking history. More impor-
tantly, we found that specimens with FISH 5′ deletion were 
more prone to negative IHC and NGS results, identifying 
discordant cases in three of 21 samples. Our results suggest 
that the 5′ deletion pattern may be vulnerable to false-posi-
tive results.
Both groups had high percentage of nuclei positive 
for ALK rearrangement—62% in split signals and 81% in 5′ 
deletion. Although discordant cases had a lower percentage 
of nuclei positive for rearrangement compared with the rest 
of our samples, they each harbored between 38% and 48% 
positive nuclei, well above the lower cutoff for ALK rearrange-
ment. Moreover, prior research has shown that the percentage 
of tumor cells with ALK rearrangement does not correlate 
with response to crizotinib.11
Our ﬁnding that ALK IHC was concordant with FISH in 
45 of 48 (94%) samples is supported by prior studies demon-
strating the ALK antibody 5A4 to have sensitivity and speci-
ﬁcity in the range of 93% and 100% relative to FISH.7,12 A 
multi-institutional Canadian study demonstrated essentially 
perfect performance of ALK IHC with the 5A4 antibody as 
compared with FISH when employing careful assay validation 
procedures.13 Because ALK FISH presents several limitations 
including high cost, requirement of specialized equipment, 
and technical challenges with result interpretation, alterna-
tive assays such as IHC and reverse transcription polymerase 
chain reaction have been evaluated.7,12,14 A risk of 5′ deletion 
on FISH representing a false-positive result suggests that 
assays such as IHC, reverse transcription polymerase chain 
reaction, or NGS could be beneﬁcial as conﬁrmatory tests 
before consideration of ALK-targeted therapy.
While 5′ deletion patients demonstrated less radio-
graphic response to crizotinib, the majority did nonetheless 
exhibit a response. This ﬁnding suggests that most 5′ deletion 
cases do in fact represent true ALK rearrangement. Additional 
studies are encouraged given the relatively small sample size 
of patients receiving crizotinib in our study. The two cases in 
this study involving FISH 5′ deletion, negative IHC, and nega-
tive NGS who had poor response to crizotinib highlight the 
potential risks of relying solely on the 5′ deletion FISH pattern 
for clinical decision making regarding ALK-targeted ther-
apy—both cases in fact harbored an alternate oncogenic driver 
mutation. Indeed, one prior study of NSCLC patients found 
ALK FISH abnormalities to be almost mutually exclusive from 
EGFR and KRAS co-mutations, with all cases of co-mutations 
occurring in samples with KRAS mutations and loss of either 
the 5′ or 3′ signal.15 A recent multi-institutional study on onco-
genic driver mutations in NSCLC similarly demonstrated that 
co-existence of ALK rearrangement with other driver muta-
tions is rare, with two of four co-mutant cases on initial testing 
subsequently proven to be false-positives on IHC and repeat 
FISH.16 Our study similarly suggests that corroborative testing 
with alternative assays may be helpful in cases with complex 
mutational ﬁndings.
Why might the 5′ deletion variant of FISH be less 
reliable in predicting true ALK rearrangement and there-
fore responsiveness to ALK-targeted therapy? The 5′ dele-
tion pattern may reflect ALK rearrangement by either true 
loss of the 5′ probe binding site via rearrangement or loss of 
the 5′ probe within the plane of the section. However, large 
deletions and structural variants affecting the binding site 
of the 5′ probe, without ALK rearrangement, may result in 
an identical FISH pattern. Such ﬁndings may be expected 
more frequently in genomically deranged tumors, such as 
smoking-related cancers. Visualization of splitting of the 5′ 
and 3′ probes may therefore be a more rigorous standard for 
ALK rearrangement than 5′ deletion and less susceptible to 
false-positive results.
Although laboratories are encouraged to clearly com-
municate ALK FISH results, detailed reporting of the speciﬁc 
FISH pattern is not explicitly required according to published 
guidelines.17 Our results suggest that ALK FISH report-
ing should be standardized to include the variant identiﬁed. 
Furthermore, our ﬁndings may also extend beyond ALK rear-
rangement as break-apart FISH is increasingly used to identify 
targetable rearrangements in ROS1 and RET.18,19 We encourage 
additional investigations to conﬁrm our observations as the 
effectiveness of therapies targeting ALK, ROS1, and RET is 
highly dependent on appropriate selection of patients with can-
cers harboring these relatively rare genotypes.
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